While Institutions Invested in Akeso, Inc. (HKG:9926) Benefited From Last Week's 5.0% Gain, Individual Investors Stood to Gain the Most
While Institutions Invested in Akeso, Inc. (HKG:9926) Benefited From Last Week's 5.0% Gain, Individual Investors Stood to Gain the Most
Key Insights
主要见解
- Akeso's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public
- A total of 17 investors have a majority stake in the company with 51% ownership
- Insiders own 20% of Akeso
- 康方生物的重要个人投资者所有权表明,关键决策受到更大公众股东的影响
- 共有17家投资者持有该公司的大部分股权,占51%的所有权。
- 内部人士拥有康方生物20%的股份
Every investor in Akeso, Inc. (HKG:9926) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors with 39% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
每位康方生物(HKG:9926)的投资者都应该意识到最强大的股东群体。而持有最大份额的群体是拥有39%股份的个人投资者。换句话说,这个群体从其对公司的投资中获得的收益最大(或损失最大)
While individual investors were the group that reaped the most benefits after last week's 5.0% price gain, institutions also received a 32% cut.
虽然散户投资者是在上周上涨5.0%后获益最多的群体,但机构也获得了32%的份额。
Let's delve deeper into each type of owner of Akeso, beginning with the chart below.
让我们深入分析一下康方生物每种所有者类型,首先是下面的图表。

What Does The Institutional Ownership Tell Us About Akeso?
机构所有权告诉我们关于康方生物什么?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构衡量其业绩的标准是一个近似于当地市场的指数。因此,他们通常更加关注包括在主要指数中的公司。
We can see that Akeso does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Akeso, (below). Of course, keep in mind that there are other factors to consider, too.
我们可以看到康方生物确实有机构投资者,他们持有公司股票的很大一部分。这意味着那些机构的分析师已经关注了这只股票,并且他们对它感到满意。但就像其他任何人一样,他们也可能出错。如果两个大型机构投资者同时试图卖出一只股票,股价大幅下跌并不少见。因此,值得检查一下康方生物过去的盈利轨迹(见下文)。当然,也要记住还有其他因素需要考虑。

We note that hedge funds don't have a meaningful investment in Akeso. With a 8.8% stake, CEO Yu Xia is the largest shareholder. Baiyong Li is the second largest shareholder owning 6.0% of common stock, and Zhongmin Wang holds about 5.0% of the company stock. Interestingly, the second and third-largest shareholders also happen to be the Top Key Executive and Member of the Board of Directors, respectively. This once again signifies considerable insider ownership amongst the company's top shareholders.
我们注意到对康方生物的对冲基金没有实质性投资。 首席执行官余霞持有8.8%的股份,是最大股东。 李白勇是第二大股东,拥有6.0%的普通股,而王中敏则持有约5.0%的公司股票。 有趣的是,第二和第三大股东恰好也是公司董事会的顶级关键执行官和成员。这再一次表明公司顶级股东中有相当可观的内部持有股份。
Looking at the shareholder registry, we can see that 51% of the ownership is controlled by the top 17 shareholders, meaning that no single shareholder has a majority interest in the ownership.
从股东注册表上看,我们可以看到前17名股东控制了51%的股份所有权,这意味着没有单一股东拥有多数股权所有权。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
研究机构持股比例是衡量和筛选股票预期表现的好方法。同样可以通过研究分析师情绪来实现。由于相当多的分析师都关注着该股票,因此你可以很容易地研究预测的增长。
Insider Ownership Of Akeso
康方生物的内部持股情况
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
虽然内部人员的精确定义可能具有主观性,但几乎所有人都认为董事会成员是内部人员。管理层最终向董事会负责。然而,如果经理是创始人或CEO,那么他们成为执行董事会成员并不罕见。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多数人认为内部所有权是积极的,因为它可以表示董事会与其他股东的利益相一致。但是,在某些场合下,这个团体的权力过于集中。
Our information suggests that insiders maintain a significant holding in Akeso, Inc.. It is very interesting to see that insiders have a meaningful HK$13b stake in this HK$65b business. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.
我们的信息表明,内部人士在康方生物有限公司持有大量股份。 看到内部人士在这个市值650亿港元的业务中拥有130亿港元的重大股份非常有趣。 大多数人会说,这表明与股东之间有很好的一致性,尤其是在如此规模的公司中。 你可以点击这里查看这些内部人士是否有买入或卖出。
General Public Ownership
一般大众所有权
The general public-- including retail investors -- own 39% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
普通公众,包括散户投资者,在该公司中拥有39%的股份,因此不能轻易被忽视。虽然这个群体不能决定一切,但它肯定会对公司的运作产生实际影响。
Private Company Ownership
私有公司的所有权
It seems that Private Companies own 9.0%, of the Akeso stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
看起来私人公司拥有9.0%的康方生物股票。私人公司可能是关联方。有时内部人士通过持有私人公司的股份而不是作为个人身份对公众公司有利益。虽然很难得出广泛的结论,但值得注意的是,这可以作为进一步研究的一个领域。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Akeso better, we need to consider many other factors. Be aware that Akeso is showing 1 warning sign in our investment analysis , you should know about...
思考持有公司股份的不同群体总是值得的。但为了更好地了解康方生物,我们需要考虑许多其他因素。请注意,康方生物在我们的投资分析中显示出1个警告信号,您应该知道这一点……
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果您像我一样,可能希望考虑这家公司是否会增长或缩小。幸运的是,您可以查看此免费报告,显示分析师对其未来的预测。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。